Zacks.com on MSN10h
Verona Pharma (VRNA) Upgraded to Buy: What Does It Mean for the Stock?Verona Pharma PLC American Depositary Share (VRNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...
Roth MKM analyst Boobalan Pachaiyappan initiated coverage of Verona Pharma (VRNA) with a Buy rating and $68 price target The firm says its ...
Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...
GlobalData on MSN17h
Newron and Myung In Pharm sign agreement for evenamide developmentUnder the agreement, Myung In Pharma is set to contribute 10% of the subjects to be enrolled for Newron's upcoming trial.
Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...
In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on Verona Pharma (VRNA – Research Report), with a price ...
Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback